[PDF] Top 20 El impacto social de la minería a gran escala en el Ecuador

... Well-designed surveys have shown discrepancies with the American Academy of Neurology guidelines on the use of ancillary tests. 1,5 ECG monitoring is routinely used by physicians to diagnose a cardiac arrest. ... See full document

... Prior ofatumumab exposure (in oncology, MS, and other auto- immune disorders) 7,14–17 has largely been intravenous, with the exception of a limited single subcutaneous dose study in ...of ... See full document

... to subcutaneous interferon beta-1a treatment was safe, and although many patients in the treatment arm dropped out, most patients tolerated methylprednisolone as an add-on to interferon ...in ... See full document

... immunogenicity study (OBSERVE, NCT01462318), which was conducted in four countries (Czech Republic, Hungary, Poland, and the ...The study was conducted according to the principles of the Declaration of ... See full document

... The interferons (beta-1a and beta-1b) are among the first Disease Modifying Drugs (DMDs) that were approved for MS. These platform therapies are frequently associated with flu-like syndrome and injection-site reactions, ... See full document

... These patients frequently present with optic neuritis, transverse myelitis, or sensory ...CIS patients not only is the risk of conversion important but also treatment decisions would be greatly aided by ... See full document

... randomized study comparing two doses of laquinimod ...gressive multiple sclerosis patients. Inclusion criteria were patients aged 18–65 years, with an Expanded Disability Status Score of ... See full document

... our study and the proportion of patients reporting ad- verse events (13%) was in line with findings from similar ...672 patients who were switched from another therapy to GA, had at least one adverse ... See full document

... MS patients with positive MRZ-AI led to the hypothesis of a ‘bystander reaction’, described as polyspecific B cell activation within the CNS ...RRMS patients, a few studies have shown negative MRZR in most ... See full document

... and ofatumumab) that deplete pre-B cells and mature B cells without affecting plasma cells or progenitor cells in the bone marrow have been studied in MS ...of patients with relapses [68]. 78% of treated ... See full document

... nineteen patients (5 males, 14 females) with MS have been included in this ...RRMS patients. The patients aged between 16 and 45 years (mean ... See full document

... et al. [17] found higher concentrations of cfDNA in serum and plasma of RA patients in comparison with healthy controls. These conflicting data on serum cfDNA levels in RA may at least in part be explained by the ... See full document

... in patients undergoing NTZ treatment can be performed based on treatment dur- ation, history of previous immunosuppression and, more recently, on serology for JCV ...[23]. Patients may also independently ... See full document

... The neuromuscular system is a complex system that provides humans with movement, from respiration and saccadic movements of the eye, to walking and standing [19,23]. The peripheral component of the neuromuscular system, ... See full document

... 17 patients with PML involving the frontal (n ⫽ 6, right; n ⫽ 4, left), parietal (n ⫽ 6, left), occipital (n ⫽ 2, right), and temporal (n ⫽ 1, right; n ⫽ 1 left) lobes or the middle cerebellar peduncle (n ⫽ 1, ... See full document

... In the two Phase III studies FREEDOMS and FREE- DOMS II [106, 107], fingolimod was found to reduce the PBV loss in RRMS patients by 36% (p < 0.001) and 33% (p = 0.0002), respectively. Whether this effect on PBV ... See full document

... of patients with ...RRMS patients that did not present OB positivity ...ON patients. Although IL-27 levels were not elevated in ON patients compared to HC, ON patients with a positive ... See full document

... ORACLE study, all the participants who converted to definite MS were offered the possibility to continue on a twice-weekly maintenance therapy with ...in patients originally ran- domized to cladribine ... See full document

... to study start while on IFN beta-1a therapy ...of patients free of ...(P,0.001). Patients on the combination of natalizumab and IFN beta-1a were less likely to have sustained disability progression ... See full document

... Hepatitis C virus (HCV) infection is a major global public health problem in both developed and developing countries [18]. It seems that the prevalence of this virus in the general population of Iran is less than 1% ... See full document